A report of a trial on 98 participants confirmed that patients with NAFLD had higher levels of STING in liver tissue, along with higher levels of inflammation and fibrosis, compared to the control group [106]. Here, STING1 is linked to metabolic dysfunction-associated steatotic liver disease.